Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 3.30
HALO's Cash to Debt is ranked higher than
64% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. HALO: 3.30 )
HALO' s 10-Year Cash to Debt Range
Min: 1.44   Max: No Debt
Current: 3.3

Equity to Asset 0.34
HALO's Equity to Asset is ranked higher than
54% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. HALO: 0.34 )
HALO' s 10-Year Equity to Asset Range
Min: -1.65   Max: 0.97
Current: 0.34

-1.65
0.97
F-Score: 3
Z-Score: 1.94
M-Score: -3.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -146.78
HALO's Operating margin (%) is ranked higher than
66% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. HALO: -146.78 )
HALO' s 10-Year Operating margin (%) Range
Min: -10677.95   Max: -35.37
Current: -146.78

-10677.95
-35.37
Net-margin (%) -152.34
HALO's Net-margin (%) is ranked higher than
66% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. HALO: -152.34 )
HALO' s 10-Year Net-margin (%) Range
Min: -10452.76   Max: -35.25
Current: -152.34

-10452.76
-35.25
ROA (%) -82.01
HALO's ROA (%) is ranked higher than
54% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. HALO: -82.01 )
HALO' s 10-Year ROA (%) Range
Min: -491.34   Max: -23.1
Current: -82.01

-491.34
-23.1
ROC (Joel Greenblatt) (%) -2350.50
HALO's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. HALO: -2350.50 )
HALO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3850.85   Max: -337.67
Current: -2350.5

-3850.85
-337.67
Revenue Growth (%) 51.80
HALO's Revenue Growth (%) is ranked higher than
96% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. HALO: 51.80 )
HALO' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 100
Current: 51.8

0
100
EBITDA Growth (%) 7.70
HALO's EBITDA Growth (%) is ranked higher than
86% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. HALO: 7.70 )
HALO' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 102.7
Current: 7.7

0
102.7
EPS Growth (%) 9.70
HALO's EPS Growth (%) is ranked higher than
87% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. HALO: 9.70 )
HALO' s 10-Year EPS Growth (%) Range
Min: -32.2   Max: 105.4
Current: 9.7

-32.2
105.4
» HALO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

HALO Guru Trades in Q3 2013

Murray Stahl 34,555 sh (New)
Chuck Royce 147,697 sh (+76.62%)
» More
Q4 2013

HALO Guru Trades in Q4 2013

Jim Simons 300,000 sh (New)
Jean-Marie Eveillard 1,294,580 sh (New)
Murray Stahl 35,532 sh (+2.83%)
Chuck Royce 112,697 sh (-23.7%)
» More
Q1 2014

HALO Guru Trades in Q1 2014

John Burbank 15,773 sh (New)
Murray Stahl 62,650 sh (+76.32%)
Jean-Marie Eveillard 1,433,780 sh (+10.75%)
Chuck Royce 66,075 sh (-41.37%)
Jim Simons 135,400 sh (-54.87%)
» More
Q2 2014

HALO Guru Trades in Q2 2014

Ken Fisher 791,760 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with HALO

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2014-03-31 New Buy0.01%$12.11 - $17.57 $ 9.1-39%15773
Jean-Marie Eveillard 2013-12-31 New Buy0.05%$9.66 - $15.7 $ 9.1-29%1294580
John Burbank 2012-12-31 Sold Out 0.17%$4.82 - $7.07 $ 9.156%0
John Burbank 2012-09-30 Add 66.67%0.07%$4.28 - $9.78 $ 9.125%500000
John Burbank 2012-06-30 Add 50%0.03%$7.32 - $13 $ 9.14%300000
John Burbank 2012-03-31 New Buy0.09%$9.22 - $13.35 $ 9.1-14%200000
George Soros 2011-12-31 Sold Out 0.0018%$5.72 - $9.73 $ 9.111%0
George Soros 2011-09-30 New Buy$5.62 - $7.29 $ 9.138%17100
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 16.85
HALO's P/B is ranked higher than
58% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. HALO: 16.85 )
HALO' s 10-Year P/B Range
Min: 7.08   Max: 139.8
Current: 16.85

7.08
139.8
P/S 18.96
HALO's P/S is ranked higher than
71% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. HALO: 18.96 )
HALO' s 10-Year P/S Range
Min: 11.07   Max: 461.55
Current: 18.96

11.07
461.55
EV-to-EBIT -11.68
HALO's EV-to-EBIT is ranked higher than
79% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. HALO: -11.68 )
HALO' s 10-Year EV-to-EBIT Range
Min: 109.1   Max: 211.2
Current: -11.68

109.1
211.2
Current Ratio 5.25
HALO's Current Ratio is ranked higher than
78% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. HALO: 5.25 )
HALO' s 10-Year Current Ratio Range
Min: 1.81   Max: 41
Current: 5.25

1.81
41
Quick Ratio 5.06
HALO's Quick Ratio is ranked higher than
78% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. HALO: 5.06 )
HALO' s 10-Year Quick Ratio Range
Min: 1.81   Max: 41
Current: 5.06

1.81
41

Valuation & Return

vs
industry
vs
history
Price/Net Cash 33.71
HALO's Price/Net Cash is ranked higher than
75% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 63.00 vs. HALO: 33.71 )
HALO' s 10-Year Price/Net Cash Range
Min: 5.35   Max: 288.25
Current: 33.71

5.35
288.25
Price/Net Current Asset Value 25.28
HALO's Price/Net Current Asset Value is ranked higher than
74% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. HALO: 25.28 )
HALO' s 10-Year Price/Net Current Asset Value Range
Min: 5.2   Max: 587
Current: 25.28

5.2
587
Price/Tangible Book 16.85
HALO's Price/Tangible Book is ranked higher than
63% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. HALO: 16.85 )
HALO' s 10-Year Price/Tangible Book Range
Min: 5.06   Max: 109.2
Current: 16.85

5.06
109.2
Price/Median PS Value 0.47
HALO's Price/Median PS Value is ranked higher than
96% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. HALO: 0.47 )
HALO' s 10-Year Price/Median PS Value Range
Min: 0.28   Max: 10.06
Current: 0.47

0.28
10.06
Forward Rate of Return (Yacktman) -5.94
HALO's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. HALO: -5.94 )
HALO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.4   Max: 14.7
Current: -5.94

3.4
14.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:RV7.Germany
Halozyme Therapeutics, Inc is a Delaware Corporation. It is a biopharmaceutical company engaged in developing and commercializing products that advance patient care. The Company's research targets the extracellular matrix, an area outside the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. The Company's research focuses mainly on human enzymes that alter the extracellular matrix. The Company's enzyme, the recombinant human hyaluronidase or rHuPH20, temporarily degrades hyaluronan, or HA, a matrix component in the skin, and facilitates the dispersion and absorption of drugs and fluids. It is also developing novel enzymes that may target other matrix structures for therapeutic benefit. The Company's Enhanze technology is the platform for the delivery of proprietary small and large molecules. The Company's operations to date have involved: organizing and staffing its operating subsidiary, Halozyme, Inc.; acquiring, developing and securing its technology; undertaking product development for its existing products and a limited number of product candidates; supporting the development of partnered product candidates; and selling Hylenex recombinant (hyaluronidase human injection). It continues to increase its focus on its proprietary product pipeline and have expanded investments in its proprietary product candidates. It currently has multiple proprietary programs in various stages of research and development. The Company's proprietary program focuses on the formulation of rHuPH20 with prandial (mealtime) insulins for the treatment of diabetes mellitus. Diabetes mellitus is an increasingly prevalent, costly condition associated with substantial morbidity and mortality. Attaining and maintaining normal blood sugar levels to minimize the long-term clinical risks is a key treatment goal for diabetic patients. It has combined rHuPH20 with an analog insulin, e.g., insulin lispro (Humalog), or Lispro-PH20, insulin aspart (Novolog), or Aspart-PH20, and insulin glulisine (Apidra), or each such combination, Analog-PH20, to accelerate their action. These Analog-PH20 combinations facilitate faster insulin dispersion in, and absorption from, the subcutaneous space into the vascular compartment, to faster insulin response. By making mealtime insulin onset faster, i.e., providing earlier insulin to the blood and thus earlier glucose lowering activity, Analog-PH20 may yield an insulin effect, more like that found in healthy, non-diabetic people. It is developing an investigational PEGylated form of rHuPH20, or PEGPH20, a new molecular entity as a candidate for the systemic treatment of tumors that accumulate HA. PEGylation refers to the attachment of polyethylene glycol to rHuPH20, now known as PEGPH20, which converts rHuPH20 from a transient and short-lived enzyme to a more stable entity in blood that can be used to treat systemic disease. HTI-50
» More Articles for HALO

Headlines

Articles On GuruFocus.com
comment on HALO May 12 2013 
comment on HALO May 12 2013 
comment on HALO May 12 2013 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) May 07 2010 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Nov 06 2009 
Halozyme Therapeutics Reports Second Quarter 2009 Financial Results Aug 07 2009 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 07 2009 
Halozyme to Host Conference Call and Webcast on August 7 to Discuss Second Quarter 2009 Financial Re Jul 31 2009 

More From Other Websites
Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer Jul 22 2014
Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer Jul 22 2014
Trade-Ideas: Halozyme Therapeutics (HALO) Is Today's "Perilous Reversal" Stock Jul 21 2014
BUZZ-U.S. Stocks on the Move-Isle of Capri, Intercloud, Rent-A-Center Jul 11 2014
Halozyme Attracting Attention With Upcoming Adcom And Potential Blockbuster Pancreatic Cancer... Jul 08 2014
Roche's Commercial Launch Of MabThera SC Triggers Milestone Payment To Halozyme Jun 25 2014
Halozyme Therapeutics To Present At The JMP Securities 2014 Healthcare Conference Jun 17 2014
Halozyme Announces Presentation Of Clinical Data At The American Diabetes Association 74th... Jun 15 2014
Halozyme Therapeutics (HALO) In A Perilous Reversal Jun 13 2014
Halozyme Therapeutics upgraded by UBS Jun 12 2014
The Zacks Analyst Blog Highlights: Clovis, Biogen, Halozyme, Ariad and Chart Industries Jun 12 2014
Why Halozyme Therapeutics Was Upgraded To 'Buy' This Morning Jun 12 2014
Biotech Stock Roundup: Biogen Hemophilia Drug Approved, Ariad & Halozyme Clinical Hold Lifted Jun 11 2014
Today's Perilous Reversal Stock: Halozyme Therapeutics (HALO) Jun 06 2014
Halozyme Therapeutics, Inc. (HALO) in Focus: Stock Surges 12.00% Jun 06 2014
Halozyme Study Clinical Hold Lifted by FDA Jun 05 2014
Shares Of Halozyme Up 14% Following FDA Removal Of Hold On PEGPH20 Jun 05 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide